The effect of landiolol on rehospitalization for heart failure in patients with acute heart failure and atrial fibrillation

The effect of landiolol on rehospitalization for heart failure in patients with acute heart failure and atrial fibrillation - The effect of landiolol on rehospitalization for heart failure in patients with acute heart failure and atrial fibrillation

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000020290

Enrollment

Registered

2015-12-28

Start date

2015-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute heart failure with tachycardic atrial fibrillation

Interventions

2 days administration of landiolol after hospitalization for acute heart failure

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Left ventricular ejection fraction more than 25% NYHA 3-4 Heart rate more than 120 bpm.

Exclusion criteria

Exclusion criteria: 1)Taking any oral beta-blocker 2)Patients required electronic shock 3)Severe valve stenosis 4)Acute coronary syndrome 5)Hyperthyroidism or its prospects 6)Hypotension less than 100mmHg 7)Pacemaker implanted or ICD implanted 8)Under respirator 9)Cardiogenic shock 10)Assessed as not being suitable for applicants

Design outcomes

Primary

Measure	Time frame
Rehospitalization for heart failure and cardiovascular death within 6 months after administration of landiolol	—

Secondary

Measure	Time frame
The effect of landiolol administration to cardiac function, sympathetic activity of heart and BNP value	—

Countries

Japan

Contacts

Public ContactKazumi Matsuda

The Cardiovascular Institute Head Office

matsuda@cvi.or.jp03-3408-2151

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026